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A 
In this thesis, we have investigated the potential of NOTCH signaling as a therapeutic 
target in non-squamous NSCLC and GBM. We developed novel in vitro and in vivo 
models to investigate whether NOTCH inhibition using small molecule inhibitors 
(GSI) when used in combination with standard of care conventional treatment with 
chemotherapy and radiotherapy improves treatment response.  
 
Chapter 2 provides a review on the role of NOTCH signaling in the intrinsic and 
acquired treatment resistance observed in NSCLC. We discuss how the NOTCH 
signaling pathway is associated with intrinsic mechanism of tumor resistance 
including its role in: cancer stem cells, ABC drug transporters, epithelial-
mesenchymal transition, hypoxia, and crosstalk with other oncogenic pathways such 
as with TP53, growth factor signaling (e.g. EGFR) tumor angiogenesis (e.g. VEGF) 
and the DNA damage response (ATM). We conclude that NOTCH-based therapeutic 
regimens in combination with radiation, and chemotherapy/targeted therapy is a 
promising strategy to further explore in NSCLC.  
 
In Chapter 3, we developed in vitro in 2D and 3D semi-high throughput drug testing 
assays to investigate whether NOTCH inhibition enhanced the anti-tumor effect of 
chemo- and chemoradiation treatments. We screened 101 FDA approved 
chemotherapeutics from the NCI library combined with RT and focused on those 
chemotherapies commonly used as part of first line treatment in NSCLC. Synergistic 
interactions (p<0.05) were observed between the clinical GSI BMS-906024 and 
chemoradiation (using cisplatin, paclitaxel, docetaxel, and crizotinib). Several 
combinations treatments were identified were NOTCH blockade enhanced the 
cytotoxic and RT effect of these treatments.  
 
In Chapter 4, we describe the development of an in vivo NSCLC tumor xenograft 
model to test the effect of these single and combined treatments on tumor growth. 
We identified drug doses of GSI and cisplatin that were effective in tumor growth 
inhibition but non-toxic. We combined GSI and cisplatin or GSI and RT in tumors 
with high oncogenic NOTCH activity and those with wildtype NOTCH signaling. 
Remarkably, we found that H460-NOTCHHigh tumors are more sensitive than the 
H460 wildtype model to cisplatin treatment. In tumors with high NOTCH activity 
we observed increased vessel density, however these vessels appeared non-
functional. H460-NOTCHHigh tumors are more resistant to radiotherapy than H460 
wildtype tumors and specific scheduling of GSI with respect to RT resulted in tumor 
cures for both tumor models.  
 
256 | Addendum 
 
 
A 
In Chapter 5, the development of an orthotopic NSCLC preclinical model in mice 
is described. We tested several models and found that H1299 NSCLC most 
reproducibly produced tumors as a single localized nodule in the lung. We compared 
two non-invasive imaging modalities; dual wavelength BLI and dual energy CBCT 
and found that they correlated. Using these models, we illustrate the effect of 
different tumor volume-based radiation treatment plan set-ups that can be delivered 
employing an image-guided, high precision small animal irradiator taking into 
account tumor margins, radiation dose-volume histogram parameters to both the 
internal and planned target volume and organs at risk (lung, heart, spinal cord). 
 
In Chapter 6, we investigated the efficacy of NOTCH inhibitors on glioma tumor 
growth and tumor resistance in vitro and in vivo. Using primary and established 
glioma cell lines and 3D spheroid models we demonstrate that NOTCH signaling 
was active but that NOTCH inhibition alone was insufficient to block tumor cell 
survival. Next, we combined clinically approved NOTCH/γ-secretase inhibitor with 
the standard of care treatment for glioblastoma: concurrent alkylating chemotherapy 
with temozolomide and radiotherapy. We also tested these combination treatments 
in an intracranial model from GBM using U87 cells and tested NOTCH inhibitors 
alone or in combination with standard of care treatment and monitored tumor growth 
response using non-invasive imaging. We found that similar to our results in vitro, 
NOTCH inhibition alone did not significantly block tumor growth but that when 
combined with temozolomide, radiotherapy or both, it significantly prolonged 
survival. In vitro and in vivo NOTCH inhibition blocked the survival of treatment 
resistant CD133 cancer stem cells.  
 
Finally, Chapter 7 summarizes the findings of this thesis and comments on the future 
challenges and opportunities for NOTCH-based interventions in cancer.  
 
 
 
 
 
 
 
